4.7 Article

Immobilization of anti-CD31 antibody on electrospun poly(ε-caprolactone) scaffolds through hydrophobins for specific adhesion of endothelial cells

期刊

COLLOIDS AND SURFACES B-BIOINTERFACES
卷 85, 期 1, 页码 32-39

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2010.10.042

关键词

Hydrophobin; Surface modification; Antibody; Self-assembled; Vascular graft

资金

  1. National Program on Key Basic Research Project of China (973 Program) [2005CB623904]
  2. NSFC [50830104]
  3. Ministry of Education of China [NCET-06-0212]
  4. Ministry of Science and Technology of China [2006DFA32360]
  5. Confocal Microscope Lab, College of Life Sciences, Nankai University

向作者/读者索取更多资源

Hydrophilicity improvement and bioactive surface design of poly(e-caprolactone) (PCL) grafts are of key importance for their application in tissue engineering. Herein, we develop a convenient approach for achieving stable hydrophilic surfaces by modifying electrospun PCL grafts with a class II hydrophobin (HFBI) coating. Static water contact angles (WCA) demonstrated the conversion of the PCL grafts from hydrophobic to hydrophilic after the introduction of amphiphilic HFBI. ATR-FTIR and XPS confirmed the presence of self-assembled HFBI films on the surface of the PCL nanofibers. The biocompatibility of the HFBI-modified PCL grafts was evaluated by cell proliferation in vitro, and by arteriovenous shunt (AV shunt) experiments ex vivo. Anti-CD31 antibody, which is specific for endothelial cells (ECs), was subsequently immobilized on the HFBI-coated PCL scaffolds through protein-protein interactions. This bioactive PCL graft was found to promote the attachment and retention of endothelial cells. These results suggest that this stepwise strategy for introducing cell-specific binding molecules into PCL scaffolds may have potential for development of vascular grafts that can endothelialize rapidly in vivo. (C) 2010 Elsevier BM. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据